cas 30450-62-5, 7-Nitro-1,2,3,4-tetrahydroquinoline

Articles about 30450-62-5Total 33 be found

Article title
Article abstract
Author
Journal number and time
Download

Controlling ground and excited state properties through ligand changes in ruthenium polypyridyl complexes
The capture and storage of solar energy requires chromophores that absorb light throughout the solar spectrum. We report here the synthesis, characterization, electrochemical, and photophysical properties of a series of Ru(II) polypyridyl complexes of the type [Ru(bpy)2(N-N)]2+ (bpy = 2,2-bipyridine; N-N is a bidentate polypyridyl ligand). In this series, the nature of the N-N ligand was altered, either through increased conjugation or incorporation of noncoordinating heteroatoms, as a way to use ligand electronic properties to tune redox potentials, absorption spectra, emission spectra, and excited state energies and lifetimes. Electrochemical measurements show that lowering the φ* orbitals on the N-N ligand results in more positive Ru3+/2+ redox potentials and more positive first ligand-based reduction potentials. The metal-to-ligand charge transfer absorptions of all of the new complexes are mostly red-shifted compared to Ru(bpy)32+ (λmax = 449 nm) with the lowest energy MLCT absorption appearing at λmax = 564 nm. Emission energies decrease from λmax = 650 nm to 885 nm across the series. One-mode Franck-Condon analysis of room-temperature emission spectra are used to calculate key excited state properties, including excited state redox potentials. The impacts of ligand changes on visible light absorption, excited state reduction potentials, and Ru3+/2+ potentials are assessed in the context of preparing low energy light absorbers for application in dye-sensitized photoelectrosynthesis cells.
Ashford, Dennis L.,Glasson, Christopher R. K.,Norris, Michael R.,Concepcion, Javier J.,Keinan, Shahar,Brennaman, M. Kyle,Templeton, Joseph L.,Meyer, Thomas J.
p. 5637 - 5646
(2014)
Read Online

Efficient and selective hydrogenation of quinolines over FeNiCu/MCM-41 catalyst at low temperature: Synergism of Fe-Ni and Ni-Cu alloys
The development of non-precious metal catalysts in heterogeneous catalytic processes is of great importance to the hydrogenation of quinolines for both theoretical and industrial applications. Herein, an effective non-precious metal catalyst, 58% Fe4Ni6Cu5/MCM-41, was developed to catalyze the hydrogenation of quinolines under the green and mild conditions, which can achieve 97.5% conversion and exceeding 98% selectivity to tetrahydroquinoline in solvent-free at low temperature of 50 °C. Moreover, the acceptable results of the reusability and gram scale-up experiments proved an industrial application potential of the as-prepared catalyst. Meanwhile, in cyclohexane system, 58% Fe4Ni6Cu5/MCM-41 catalyst can further realize a higher activity of the hydrogenation at a lower temperature of 40 °C, achieving 98.2% conversion and 98% selectivity to tetrahydroquinoline. The existence of Fe-Ni and Ni-Cu alloys in Fe4Ni6Cu5/MCM-41 catalyst was demonstrated by TEM, XRD, XPS, H2-TPD, and Raman spectroscopy. And, Fe-Ni and Ni-Cu alloys can be well dispersed onto MCM-41 molecular sieves. For Fe4Ni6Cu5/MCM-41 catalyst, quinoline molecules can be adsorbed by Fe3+ species on the surface of Fe-Ni alloy through the coordination, while hydrogen molecules can be adsorbed and activated by Ni-Cu alloy. Under the synergism of Fe-Ni and Ni-Cu alloys, the highly effective and selective hydrogenation of quinolines was achieved at low temperature and in solvent-free system. The present approach offers a prospective idea for building non-precious metal catalysts to realize the effective hydrogenation of N-heterocyclic compounds under mild conditions.
Cao, Zhe,He, Zhen-Hong,Liu, Zhao-Tie,Wang, Dan,Wang, Junlei,Wang, Kuan,Wang, Weitao,Yang, Yang,Zhang, Rong-Rong
(2022/03/03)

Development of versatile and potent monoquaternary reactivators of acetylcholinesterase
To date, the only treatments developed for poisoning by organophosphorus compounds, the most toxic chemical weapons of mass destruction, have exhibited limited efficacy and versatility. The available causal antidotes are based on reactivation of the enzyme acetylcholinesterase (AChE), which is rapidly and pseudo-irreversibly inhibited by these agents. In this study, we developed a novel series of monoquaternary reactivators combining permanently charged moieties tethered to position 6- of 3-hydroxypyridine-2-aldoxime reactivating subunit. Highlighted representatives (21, 24, and 27; also coded as K1371, K1374, and K1375, respectively) that contained 1-phenylisoquinolinium, 7-amino-1-phenylisoquinolinium and 4-carbamoylpyridinium moieties?as peripheral anionic site ligands, respectively, showed efficacy superior or comparable to that of the clinically used standards. More importantly, these reactivators exhibited wide-spectrum efficacy and were minutely investigated via determination of their reactivation kinetics in parallel with molecular dynamics simulations to study their mechanisms of reactivation of the tabun-inhibited AChE conjugate. To further confirm the potential applicability of these candidates, a mouse in vivo assay was conducted. While K1375 had the lowest acute toxicity and the most suitable pharmacokinetic profile, the oxime K1374 with delayed elimination half-life was the most effective in ameliorating the signs of tabun toxicity. Moreover, both in vitro and in vivo, the versatility of the agents was substantially superior to that of clinically used standards. Their high efficacy and broad-spectrum capability make K1374 and K1375 promising candidates that should be further investigated for their potential as nerve agents and insecticide antidotes.
Gorecki, Lukas,Hepnarova, Vendula,Karasova, Jana Zdarova,Hrabinova, Martina,Courageux, Charlotte,Dias, José,Kucera, Tomas,Kobrlova, Tereza,Muckova, Lubica,Prchal, Lukas,Malinak, David,Jun, Daniel,Musilek, Kamil,Worek, Franz,Nachon, Florian,Soukup, Ondrej,Korabecny, Jan
p. 985 - 1001
(2021/02/03)

Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift
Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.
Thorat, Shivaji A.,Lee, Yoonji,Jung, Aeran,Ann, Jihyae,Ahn, Songyeon,Baek, Jisoo,Zuo, Dongxu,Do, Nayeon,Jeong, Jin Ju,Blumberg, Peter M.,Esch, Timothy E.,Turcios, Noe A.,Pearce, Larry V.,Ha, Hee-Jin,Yoo, Young Dong,Hong, Sunhye,Choi, Sun,Lee, Jeewoo
p. 370 - 384
(2021/02/05)

Catalytic-Type Excited-State N?H Proton-Transfer Reaction in 7-Aminoquinoline and Its Derivatives
7-Aminoquinoline (7AQ) and various amino derivatives thereof (-NHR) have been strategically designed and synthesized to study their excited-state proton-transfer (ESPT) properties. Due to the large separation between the proton donor -NHR and the acceptor
Chang, Kai-Hsin,Liu, Ying-Hsuan,Liu, Jiun-Chi,Peng, Yu-Chiang,Yang, Yu-Hsuan,Li, Zhi-Bin,Jheng, Ren-Hua,Chao, Chi-Min,Liu, Kuan-Miao,Chou, Pi-Tai
p. 14972 - 14982
(2019/11/13)

Ordered Porous Nitrogen-Doped Carbon Matrix with Atomically Dispersed Cobalt Sites as an Efficient Catalyst for Dehydrogenation and Transfer Hydrogenation of N-Heterocycles
Single-atom catalysts (SACs) have been explored widely as potential substitutes for homogeneous catalysts. Isolated cobalt single-atom sites were stabilized on an ordered porous nitrogen-doped carbon matrix (ISAS-Co/OPNC). ISAS-Co/OPNC is a highly efficient catalyst for acceptorless dehydrogenation of N-heterocycles to release H2. ISAS-Co/OPNC also exhibits excellent catalytic activity for the reverse transfer hydrogenation (or hydrogenation) of N-heterocycles to store H2, using formic acid or external hydrogen as a hydrogen source. The catalytic performance of ISAS-Co/OPNC in both reactions surpasses previously reported homogeneous and heterogeneous precious-metal catalysts. The reaction mechanisms are systematically investigated using first-principles calculations and it is suggested that the Eley–Rideal mechanism is dominant.
Han, Yunhu,Wang, Ziyun,Xu, Ruirui,Zhang, Wei,Chen, Wenxing,Zheng, Lirong,Zhang, Jian,Luo, Jun,Wu, Konglin,Zhu, Youqi,Chen, Chen,Peng, Qing,Liu, Qiang,Hu,Wang, Dingsheng,Li, Yadong
supporting information
p. 11262 - 11266
(2018/08/28)

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroqu
-
Page/Page column 93; 94

(2016/12/26)

Ezrin inhibitors and methods of making and using
The invention encompasses compound and pharmaceutical composition comprising the compound of the following Formula (I): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growth of a cancer cell.
-
Page/Page column 55; 58; 59

(2017/01/05)

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
-
Paragraph 0616

(2015/09/22)

Selective anti-markovnikov cyclization and hydrofluorination reaction in superacid HF/SbF5: A tool in the design of nitrogen-containing (fluorinated) polycyclic systems
The selective synthesis of tetrahydroquinolines and fluorinated arylamines was performed in superacid HF/SbF5 through a superelectrophilic ammonium-carbenium activation process. This anti-Markovnikov oriented reaction was applied to the straightforward synthesis of highly valued (fluorinated) nitrogen-containing heterocyclic compounds.
Compain, Guillaume,Bonneau, Celine,Martin-Mingot, Agnes,Thibaudeau, Sebastien
p. 4463 - 4472
(2013/06/05)

Synthesis of complex ortho-allyliodoarenes by employing the reductive iodonio-claisen rearrangement
The reductive iodonio-Claisen rearrangement (RICR), involving complex aromatic λ3-iodanes and allyltrimethylsilane, was investigated. The RICR reaction of complex substituted aromatic hypervalent iodine (III) compounds and an allylmetal partner was conducted. The anionic oxy Cope rearrangement was found to be approximately 1010 to 1017 times faster than the neutral oxy Cope rearrangement due to weakening of the adjacent C-C bond by the oxygen anion. The results also indicate that the steric and electronic nature of the aromatic λ3-iodanes is the dominant factor influencing the [3,3]-sigmatropic rearrangement reaction. The removal of tert-butyl ether protecting group by using trifluroacetic acid in dichloromethane in the presence of triisopropylsilane gives the natural product broussin in 39% yield.
Khatri, Hem Raj,Zhu, Jianglong
supporting information
p. 12232 - 12236
(2012/11/07)

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
-
(2012/12/14)

Anti-Markovnikov additions to N-allylic derivatives involving ammonium-carbenium superelectrophiles
Anti-Markovnikov additions to non-conjugated unsaturated amines in superacid are reported. In situ NMR studies, DFT calculations and labelled substrates reactions support the involvement of new ammonium-carbenium superelectrophiles in this original proces
Compain, Guillaume,Martin-Mingot, Agnes,Frapper, Gilles,Bachmann, Christian,Jouannetaud, Marie-Paule,Thibaudeau, Sebastien
supporting information; experimental part
p. 5877 - 5879
(2012/08/14)

Synthesis of 6-nitro-1,2,3,4-tetrahydroquinoline: An experimental and theoretical study of regioselective nitration
A revision of the literature on the nitration of tetrahydroquinolines yielded a number of inconsistencies. Thus, we have carried out a thorough study on the nitration of tetrahydroquinoline and several of its N-protected derivatives both experimentally and at theoretical level. Usually, nitration is carried out in acidic conditions and, thus, tetrahydroquinoline would be N-protonated; however, if the amino group is protected, the neutral system will be the one undergoing nitration. Different protecting groups have been explored varying, not only electronic and steric effects, but also deprotection conditions. Additionally, different reagents and reaction conditions have been investigated. From this study we have been able to achieve total regioselectivity for nitration at the 6-position. A very detailed NMR study has been carried out to unequivocally characterise the four nitro isomers. In parallel, a computational study has been performed that is in agreement with the experimental results obtained. With this purpose, all the σ complexes of the four nitro isomers neutral and N-protonated have been optimized both in gas and water condensed phases by using the B3LYP/6-31++G* level of computation. The selective nitration of tetrahydroquinoline was studied. N-Protecting groups presence or absence directs nitration at different positions. Regioselective nitration at 6-position was achieved. A DFT computational study of all nitro σ complexes was performed in gas and water phases, the results are consistent with the experiments. Copyright
Cordeiro, Alessandra,Shaw, Julian,O'Brien, John,Blanco, Fernando,Rozas, Isabel
experimental part
p. 1504 - 1513
(2011/04/25)

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
-
(2012/04/23)

A versatile route to red-emitting carbopyronine dyes for optical microscopy and nanoscopy
Biological microscopy favors photostable fluorescent markers with large fluorescence quantum yields, low dark triplet state population, good biocompatibility and absorption and emission maxima in the near-infrared, where cellular autofluorescence is minimized. In the present study, carbopyronines absorbing around 640 nm and emitting at around 660 nm, with a low intersystem crossing rate (kisc ≈ 0.5×106 s-1) and excellent properties for cellular imaging were synthesized. A general synthetic route to carbopyronines with functional groups variable in the final steps of the synthesis or in the resulting fluorescent dye is presented. Possessing two 2-me-thoxyethyl groups, the parent dye is soluble in water and most organic solvents. Demethylation of the dye or its precursors is straightforward, clean, and furnishes compounds with one or two 2-hydroxyethyl groups, which can be used for further transformations. Modifications in the linker-containing carboxy group are also possible. A multistep synthesis of the dye starting from a simple precursor and utilizing a single temporary protective group is described. The presented approach may be further applied to the design of caged carbopyronines.
Kolmakov, Kirill,Belov, Vladimir N.,Wurm, Christian A.,Harke, Benjamin,Leutenegger, Marcel,Eggeling, Christian,Hell, Stefan W.
supporting information; experimental part
p. 3593 - 3610
(2010/11/18)

Spectrofluorimetric determination of trace nitrite with a novel fluorescent probe
A simple, sensitive and selective fluorimetric determination for trace nitrites was developed using an unsymmetrical rhodamine with a high fluorescence quantum yield and large Stokes shift. The method is based on the reaction of the unsymmetrical rhodamine with nitrite in an acidic medium to form a nitroso product, which has much lower fluorescence because the electron-withdrawing effect of the nitroso group influences the system of p-π conjugation between N atom and benzene ring. Under optimum conditions, the fluorescence quenching intensity is linear over a nitrite concentration range of 1.0 × 10-8 to 3.5 × 10-7 M. The detection limit is 2.0 × 10-10 M (S/N = 3). The method was applied to the determination of nitrite in tap water and lake water with satisfactory results. The mechanism for the reaction is also reported.
Liu, Qing-Hao,Yan, Xi-Long,Guo, Jin-Chun,Wang, Dong-Hua,Li, Lei,Yan, Fan-Yong,Chen, Li-Gong
scheme or table
p. 789 - 793
(2009/12/01)

SULFONAMIDE DERIVATIVES
The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R1, R2, R3, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
-
Page/Page column 15

(2008/12/06)

Photostable, amino reactive and water-soluble fluorescent labels based on sulfonated rhodamine with a rigidized xanthene fragment
Highly water soluble fluorescent dyes were synthesized and transformed into new amino reactive fluorescent labels for biological microscopy. To this end, rhodamine 8 (prepared from 7-hydroxy-1,2,3,4-tetrahydroquinoline (7) and phthalic anhydride in 85% aq. H3PO4) was sulfonated with 30% SO3 in H2SO4 and afforded the water soluble disulfonic acid 3 a (64%). Amidation of the carboxy group in 3 a with 2-(methylamino)ethanol in the presence of O-(7-azabenzotriazol-1-yl)-N,N,N, N′-tetramethyluronium·PF6- (HATU) led to alcohol 3b (66%), which was transformed into the amino reactive mixed carbonate 3d with di(N-succinimidyl)carbonate and Et3N, Reaction of the carboxy group in 3a with MeNH(CH2)2CO2Me and N,N,N′,N′-tetramethyl-O-(N-succinimidyl)-uronium-BF4 - (TSTU) yielded methyl ester 13. After saponification of the aliphatic carboxy group in 13, the compound was converted into NHS-ester 3e (using HATU and Et3N). Heating of 7 with trimellitic anhydride in H3PO4 gave a mixture of dicarboxylic acids 14 and 15 (1:1). Regioisomer 15 was isolated, sulfonated with 30% SO3 in H 2SO4, and disulfonic acid 3f was used for the synthesis of the mono NHS-ester 3g, in which the sterically unhindered carboxy group was selectively activated (with n-hydroxysuccinimide, HATU, and Et3N). The sulfonated rhodamines 3 b, c and f are soluble in water (up to 0.1 M), have excellent photostabilities and large fluorescence quantum yields. Subdiffraction resolution images of tubulin filaments of mammalian cells stained with these dyes illustrate their applicability as labels for stimulated emission depletion microscopy and other fluorescence techniques.
Boyarskiy, Vadim P.,Belov, Vladimir N.,Medda, Rebecca,Hein, Birka,Bossi, Mariano,Hell, Stefan W.
supporting information; experimental part
p. 1784 - 1792
(2009/04/07)

QUINAZOLINE DERIVATIVES
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
-
Page/Page column 108-109

(2008/06/13)

N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1
Starting from the high throughput screening hit (3), novel N-tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl carboxamides have been identified as potent antagonists of the ion channel TRPV1. The N-quinolinylnicotinamide (46) showed excellent potenc
Westaway, Susan M.,Chung, Ying-Kit,Davis, John B.,Holland, Vicky,Jerman, Jeffrey C.,Medhurst, Stephen J.,Rami, Harshad K.,Stemp, Geoffrey,Stevens, Alexander J.,Thompson, Mervyn,Winborn, Kim Y.,Wright, James
p. 4533 - 4536
(2007/10/03)

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
-
Page/Page column 48

(2008/06/13)

QUINAZOLINE DERIVATIVES
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
-
Page/Page column 166

(2008/06/13)

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
-
Page/Page column 25

(2010/11/23)

Vanilloid receptor ligands and their use in treatments
Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
-
(2008/06/13)

4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6- g]quinolines: Potent, nonsteroidal androgen receptor agonists
A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.
Higuchi, Robert I.,Edwards, James P.,Caferro, Thomas R.,Ringgenberg, Josef D.,Kong, James W.,Hamann, Lawrence G.,Arienti, Kristen L.,Marschke, Keith B.,Davis, Robert L.,Farmer, Luc J.,Jones, Todd K.
p. 1335 - 1340
(2007/10/03)

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

Steroid receptor modulator compounds and methods
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

Steroid receptor modulator compounds and methods
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiting steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)

Tricyclic steroid receptor modulator compounds and methods
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
-
(2008/06/13)